Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2020 Dec:54:102203.
doi: 10.1016/j.ajp.2020.102203. Epub 2020 Jun 20.

Psychiatric adverse events with hydroxychloroquine during COVID-19 pandemic

Stip Emmanuel  1 , Linda Östlundh  2
Affiliations
Case Reports

Psychiatric adverse events with hydroxychloroquine during COVID-19 pandemic

Stip Emmanuel et al. Asian J Psychiatr. 2020 Dec.

Abstract

  1. •

    HCQ, well known in rheumatology, dermatology and tropical medicine is now considered in the treatment and prophylaxy for the SARS-CoVid19.

  2. •

    Mental and neurological manifestations should be assessed following the use of hydrochloroquine particularly following prophylactic use.

  3. •

    For acute malaria studies, HCQ was associated with high prevalenceof mental neurological manifestations amongst anti-malaria drugs.

  4. •

    Recommendations of using HCQ in COVID are variable and sometimes contradictory depending on agencies and countries.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest

References

    1. Abena Pascale M. Chloroquine and hydroxychloroquine for the prevention or treatment of Novel Coronavirus Disease (COVID-19) in Africa: caution for inappropriate off-label use in healthcare settings. Am. J. Trop. Med. Hyg. 2020;102(6):1184–1188. doi: 10.4269/ajtmh.20-0290. - DOI - PMC - PubMed
    1. Bitta M.A., Kariuki S.M., Mwita C., Gwer S., Mwai L., Newton C.R.J.C. Antimalarial drugs and the prevalence of mental and neurological manifestations: a systematic review and meta-analysis. Wellcome Open Res. 2017;2:13. doi: 10.12688/wellcomeopenres.10658.2. Published 2017 Jun 2. - DOI - PMC - PubMed
    1. Colson P., Rolain J.M., Raoult D. Chloroquine for the 2019 novel coronavirus. Int. J. Antimicrob. Agents. 2020:105923. - PMC - PubMed
    1. Cortegiani A., Ingoglia G., Ippolito M Giarratano A., Einav S. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. J. Crit. Care. 2020 doi: 10.1016/j.jcrc.2020.03.005. (published online March 10.) - DOI - PMC - PubMed
    1. Duparc S., Chalon S., Miller S. Neurological and psychiatric safety of tafenoquine in Plasmodium vivax relapse prevention: a review. Malar. J. 2020;111 - PMC - PubMed